Now Enrolling Patients with Myelofibrosis
Phase III studies investigating INCB018424—
an oral JAK1/JAK2 inhibitor
In this Web site you will find information on 2 clinical trials, COMFORT-I and COMFORT-II, currently evaluating the investigational agent INCB018424 for the treatment of myelofibrosis. Additional useful resources include trial recruitment information and brief overviews of selected topics such as myelofibrosis, the JAK pathway, and preliminary clinical results.